Friday 6 November 2026 Export RGNX’s income statement to Excel — free account

REGENXBIO Inc.

RGNX Healthcare Biotechnology

REGENXBIO Inc.’s revenue for fiscal 2025 (year ended December 2025) was $170.4 million, up 104.5% from fiscal 2024.

Revenue: −69.2%
EPS: +48.0%
Free cash flow: +168.1%

Quarter to September 2026, against a year earlier

Insider buying

7.56 0.18 +2.44%

Follow RGNX

Alert me

Market cap: $487.2M
P/E: 0.0×
Fwd P/E: −2.2×
Dividend yield: —
F-score: 5/9
Altman Z: −2.57
Beneish M: −2.77
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Bought, $m 0.95

Sold, $m 0.94

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	—	—	1	—	—	—
Sell	—	—	—	1	—	1	1	1	—	—	—	—

Insider Ownership 6.44%

Capital & Financial Ratios $m

Size

Market Cap 487.18

Revenue ttm 153.91

Net income ttm (175.23)

Free cash flow ttm (154.80)

Net debt Q (251.20)

Valuation

P/E 0.00

Forward P/E (2.21)

Price / sales 3.21

Forward P/S Powerpack

Price / FCF 0.00

Price / book 3.33

Financial health

Current ratio Q 4.74

Debt / equity Q 0.00

Interest coverage Q (4.76)

Growth

Revenue growth Q −69.19%

Operating income growth Q +32.20%

EPS, this year +16.23%

EPS, next year A +11.34%

Revenue, next year A −2.61%

EPS, past 5 yrs —

EPS, next 5 yrs A +24.43%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 17.01%

10-year low 10-year high

P/B against its own 10 years 67.63%

10-year low 10-year high

EV/Sales against its own 10 years 14.51%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	275	235	230	251
Receivables	25	20	26	9
Inventory	—	—	—	—
Other	20	14	13	48
	335	278	281	321

	2023	2024	2025	Q'26
Payables	23	23	21	13
ST’ Debt	—	—	—	—
Other	51	34	40	12
	130	103	118	68

Compound Annual Growth %

	10y	5y	3y
Sales	36.50%	1.97%	14.78%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(7.20%)	(22.93%)	(41.62%)

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate 0.12 Actual 0.43

−2.04 −1.34 −0.64 0.05 0.75

Q3 FY25 Beat +0.18

Q4 FY25 Miss −0.29

Q1 FY26 Miss −0.36

Q2 FY26 Beat +0.31

Q3 FY26 — Nov 5

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q3 FY25	−1.38	−1.20	Beat by 0.18
Q4 FY25	−1.01	−1.30	Miss by 0.29
Q1 FY26	−1.36	−1.72	Miss by 0.36
Q2 FY26	0.12	0.43	Beat by 0.31
Q3 FY26	−1.35	—	Reports 5 November 2026

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(1.72)	0.43	(0.62)	—	—
’25	0.12	(1.38)	(1.20)	(1.30)	(3.76)
’24	(1.38)	(1.05)	(1.17)	(1.01)	(4.59)
’23	(1.53)	(1.66)	(1.41)	(1.43)	(6.02)
’22	(1.79)	(1.58)	(1.75)	(1.38)	(6.50)
’21	(1.20)	(1.36)	(1.37)	6.67	2.91
’20	(1.08)	(0.91)	0.23	(1.24)	(2.98)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	6	108	9	—	—
’25	89	21	30	30	170
’24	16	22	24	21	83
’23	19	20	29	22	90
’22	22	33	27	31	113
’21	19	22	31	399	470
’20	18	17	99	21	155

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(76)	(62)	—	—	—
’25	34	(49)	(56)	(52)	(124)
’24	(55)	(45)	(41)	(32)	(173)
’23	(81)	(47)	(49)	(41)	(218)
’22	(56)	(62)	(50)	(39)	(207)
’21	(44)	(36)	(43)	341	219
’20	(36)	(21)	(36)	39	(54)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(77)	(63)	38	—	—
’25	33	(50)	(56)	(53)	(126)
’24	(56)	(46)	(41)	(33)	(176)
’23	(86)	(50)	(51)	(42)	(228)
’22	(67)	(71)	(56)	(45)	(238)
’21	(75)	(56)	(61)	327	135
’20	(40)	(25)	(43)	27	(81)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Sep ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	5	10	219	35	155	470	113	90	83	170	154		+49.4%	166	205	363	+28.7%
	Gross margin, %	79.10	83.56	95.59	76.61	76.89	88.98	51.61	58.76	59.72	88.09	87.54		+9.0 pt	Powerpack REGENXBIO Inc.’s next three years, line by line Analysts expect revenue to grow 28.7% a year to 2028 — slower than the 49.4% of the last 9 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(63)	(73)	104	(97)	(106)	141	(280)	(264)	(227)	(194)	(175)		+13.2%
	EBT margin, %	(1,381.61)	(704.02)	47.65	(276.70)	(68.59)	30.03	(248.75)	(292.15)	(272.54)	(113.75)	(113.85)		+1,267.9 pt
	Net income	(63)	(73)	100	(95)	(111)	128	(280)	(263)	(227)	(194)	(175)		+13.3%
Per share, $
Per share, $	Revenue	0.17	0.35	6.54	0.96	4.15	11.08	2.61	2.06	1.68	3.30	2.36		+38.7%
	Earnings	(2.38)	(2.45)	2.99	(2.58)	(2.98)	3.01	(6.50)	(6.02)	(4.59)	(3.76)	(3.21)		+5.2%
	Cash flow	(1.84)	(1.94)	3.13	(2.94)	(1.45)	5.16	(4.81)	(4.99)	(3.50)	(2.40)	(2.33)		+3.0%
	Capex	(0.31)	(0.24)	(0.40)	(0.32)	(0.72)	(1.98)	(0.71)	(0.23)	(0.05)	(0.05)	(0.04)		(18.9%)
	Free cash flow	(2.15)	(2.18)	2.73	(3.25)	(2.17)	3.17	(5.52)	(5.22)	(3.55)	(2.45)	(2.37)		+1.5%
	Book value	6.12	6.13	15.22	12.27	10.13	18.01	11.96	7.13	5.24	1.99	2.27		(11.7%)
	Shares, m	26	30	33	37	37	42	43	44	50	52	56		+7.7%
Valuation, ×
Valuation, ×	P/E	0.00	0.00	13.15	0.00	0.00	11.12	0.00	0.00	0.00	0.00	0.00		2.4
	P/S	106.46	99.90	6.42	42.66	10.94	2.95	8.52	8.89	4.59	4.36	3.21		29.6
	P/B	3.02	5.67	2.76	3.34	4.48	1.82	1.86	2.57	1.47	7.23	3.33		3.4
	EV/Sales	86.95	84.43	4.98	34.42	7.90	1.99	5.33	5.90	1.85	3.04	1.61		23.7
	EV/FCF	(7.04)	(13.47)	11.91	(10.16)	(15.09)	6.95	(2.52)	(2.33)	(0.88)	(4.10)	(1.60)		(3.7)
Cash, $m
Cash, $m	Operating cash flow	(49)	(58)	105	(108)	(54)	219	(207)	(218)	(173)	(124)	(152)		+11.0%
	Capex	(8)	(7)	(13)	(12)	(27)	(84)	(31)	(10)	(2)	(2)	(3)		(12.6%)
	Free cash flow	(57)	(65)	91	(119)	(81)	135	(238)	(228)	(176)	(126)	(155)		+9.3%
Balance, $m
Balance, $m	Working capital	84	154	316	311	450	388	286	205	175	163	253		+7.7%
	Net debt	(90)	(161)	(314)	(296)	(476)	(457)	(365)	(275)	(235)	(230)	(251)		+11.1%
	Shareholders’ equity	162	183	509	450	378	764	516	312	260	103	148		(4.9%)
Returns, %
Returns, %	ROA	(31.95)	(39.40)	26.92	(18.19)	(18.45)	14.03	(28.79)	(37.45)	(43.68)	(42.19)	(35.36)		(10.2) pt
	ROIC	(56.57)	(213.15)	28.25	(60.48)	0.00	32.58	(108.41)	(459.32)	(584.21)	0.00	0.00		+56.6 pt
	ROE	(33.27)	(42.45)	28.89	(19.76)	(26.87)	22.39	(43.78)	(63.65)	(79.49)	(107.00)	(113.24)		(73.7) pt
People
People	Employees	107	139	192	257	306	372	401	344	353	371	—		+14.8%
	Revenue/emp, $m	0.04	0.07	1.14	0.14	0.51	1.26	0.28	0.26	0.24	0.46	—		+30.1%

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 6 Nov 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
SLBT SL SCIENCE HLDG	$504.7M	—	—	—	—	—	—	—	Compare
PBYI Puma Biotechnology, Inc.	$504.3M	15.3×	24.2×	+7.75% (above 0%: growing)	+33.33% (above 0%: growing)	−88.45% (below 0%: shrinking)	77.92%	13.42%	Compare
OVID Ovid Therapeutics	$503.9M	— (loss-making)	— (loss-making)	+463.85% (above 0%: growing)	n/m	−268.54% (below 0%: shrinking)	100.00%	(2,141.61%)	Compare
CAPR Capricor Therapeutics, Inc.	$500.0M	— (loss-making)	— (loss-making)	−7.92% (below 0%: shrinking)	n/m	−72.88% (below 0%: shrinking)	100.00%	0.00%	Compare
DMAC DiaMedica Therapeutics, Inc.	$487.5M	— (loss-making)	— (loss-making)	—	n/m	−6.75% (below 0%: shrinking)	0.00%	0.00%	Compare
RGNX REGENXBIO Inc.	$487.2M	— (loss-making)	— (loss-making)	−69.19% (below 0%: shrinking)	n/m	+168.05% (above 0%: growing)	87.55%	(387.84%)
INDP Indaptus Therapeutics, Inc.	$485.3M	— (loss-making)	—	—	n/m	+52.03% (above 0%: growing)	0.00%	0.00%	Compare
CBIO Crescent Biopharma, Inc.	$480.6M	— (loss-making)	— (loss-making)	+1,038,900.00% (above 0%: growing)	n/m	−7.04% (below 0%: shrinking)	100.00%	0.00%	Compare
MDXG MiMedx Group, Inc	$478.6M	— (loss-making)	— (loss-making)	−45.23% (below 0%: shrinking)	n/m	−87.21% (below 0%: shrinking)	79.80%	(18.79%)	Compare
Median of peers	$493.7M	—	—	+7.75%	—	−72.88%	79.80%	0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 14 April 2026

Ownership

Directors and executive officers, together 14.22%

Redmile Group, LLC One Letterman Drive Building D, Suite D3-300 San Francisco, CA 9.99%

JPMorgan Chase & Co. 7.17%

Allan M. Fox 5.92%

Entities Affiliated with Allan M. Fox Bryn Mawr Trust Company 5.58%

Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

REGENXBIO Inc. (RGNX) Latest News

6 Nov

Impact 4 · 1:15 PM · MarketBeat transcript

REGENXBIO Q3 Earnings Call Highlights

5 Nov

Impact 3 · 2:33 PM · The Motley Fool transcript

REGENXBIO (RGNX) Q3 2026 Earnings Call Transcript

Impact 3 · 7:05 AM · PR Newswire

REGENXBIO Reports Third Quarter 2026 Financial Results and Operational Highlights

29 Oct

Impact 4 · 9:00 AM · Zacks

Regenxbio (RGNX) Expected to Beat Earnings Estimates: Should You Buy?

Impact 3 · 7:05 AM · PR Newswire

REGENXBIO to Host Conference Call on November 5 to Discuss Third Quarter 2026 Financial Results and Operational Highlights

28 Oct

Impact 3 · 4:22 AM · Trefis

Has The Story Under Krystal Biotech Stock Run Out?

21 Oct

Impact 4 · 5:02 PM · MarketBeat

REGENXBIO Eyes Q4 Pivotal Readout for One-Time Wet AMD Gene Therapy

12 Oct

Impact 4 · 7:05 AM · PR Newswire

REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20

5 Oct

Impact 4 · 7:42 AM · Stocktwits

Regenxbio’s Two Lead Gene Therapies Back Mizuho’s Nearly 200% Upside Call

25 Sep

Impact 4 · 9:37 AM · Investing.com

Regenxbio stock gains on positive gene therapy trial data

24 Sep

Impact 3 · 7:17 PM · PR Newswire

REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting

4 Sep

Impact 4 · 8:23 PM

Regenxbio’s Gene Therapy Faces Another FDA Setback in Hunter Syndrome

25 Aug

Impact 4 · 11:07 AM

RGNX Stock Slumps 25% on FDA Clinical Hold for RGX-121 Gene Therapy

Impact 4 · 6:50 AM · Stocktwits

Regenxbio’s RGX-121 Setback Carries A Potential Cash Risk, Warns Clear Street

Impact 4 · 6:21 AM · hospitalmanagement.net

FDA places clinical hold on REGENXBIO’s RGX-121 in MPS II trial

24 Aug

Impact 4 · 3:18 PM · Stocktwits

RGNX Stock On Track For Worst Day In Over Three Months — BofA Says Buy Despite ‘Disappointing’ FDA Hold On Gene Therapy

Impact 4 · 10:18 AM

Why Regenxbio Halted Its Gene Therapy Trial—and Why the Stock Is Tumbling

Impact 4 · 9:02 AM · Stocktwits

Why Did RGNX Stock Crash Today?

Impact 4 · 8:45 AM · InvestorsHub

REGENXBIO Shares Plunge After FDA Places Clinical Hold on RGX-121

Impact 4 · 8:39 AM

Regenxbio Stock Sinks 22% Following Surprise Finding in Gene Therapy Trial

Impact 4 · 7:55 AM · biopharmadive.com

Safety concerns spur FDA to again halt testing of Regenxbio gene therapy

Impact 4 · 7:05 AM

REGENXBIO Announces Regulatory Update on RGX-121 for MPS II

7 Aug

Impact 3 · 7:03 AM · MarketBeat transcript

REGENXBIO Q2 Earnings Call Highlights

6 Aug

Impact 4 · 3:02 PM transcript

Regenxbio Inc (RGNX) (Q2 2026) Earnings Call Highlights: Cash Runway Extended into Q4 2027 on ...

Impact 3 · 9:50 AM

Regenxbio (RGNX) Beats Q2 Earnings and Revenue Estimates

Impact 3 · 7:05 AM

REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights

18 Jul

Impact 4 · 2:55 PM

REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting

16 Jul

Impact 3 · 6:36 PM · Stocktwits

RGNX Stock Slumps 15% After-Hours — What’s Driving The Selloff?

Impact 3 · 4:26 PM

REGENXBIO Announces Proposed Public Offering of Common Stock

29 Jun

Impact 4 · 7:05 AM

REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone

REGENXBIO Inc.

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

REGENXBIO Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 14 April 2026

Ownership

REGENXBIO Inc. (RGNX) Latest News

6 Nov

5 Nov

29 Oct

28 Oct

21 Oct

12 Oct

5 Oct

25 Sep

24 Sep

4 Sep

25 Aug

24 Aug

7 Aug

6 Aug

18 Jul

16 Jul

29 Jun

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

REGENXBIO Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 14 April 2026

Ownership

REGENXBIO Inc. (RGNX) Latest News

6 Nov

5 Nov

29 Oct

28 Oct

21 Oct

12 Oct

5 Oct

25 Sep

24 Sep

4 Sep

25 Aug

24 Aug

7 Aug

6 Aug

18 Jul

16 Jul

29 Jun

Stockrow Weekly